LT3277682T - 6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių - Google Patents

6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių

Info

Publication number
LT3277682T
LT3277682T LTEP16718910.9T LT16718910T LT3277682T LT 3277682 T LT3277682 T LT 3277682T LT 16718910 T LT16718910 T LT 16718910T LT 3277682 T LT3277682 T LT 3277682T
Authority
LT
Lithuania
Prior art keywords
morpholinyl
pyrazolyl
purine derivatives
pi3k inhibitors
pi3k
Prior art date
Application number
LTEP16718910.9T
Other languages
English (en)
Inventor
Kirandeep SAMBY
Yogesh SURASE
Sagar AMALE
Suresh GORLA
Priyanka PATEL
Ashwani Verma
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of LT3277682T publication Critical patent/LT3277682T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
LTEP16718910.9T 2015-03-30 2016-03-29 6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių LT3277682T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN878DE2015 2015-03-30
PCT/IB2016/051762 WO2016157074A1 (en) 2015-03-30 2016-03-29 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
LT3277682T true LT3277682T (lt) 2019-06-25

Family

ID=55854760

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16718910.9T LT3277682T (lt) 2015-03-30 2016-03-29 6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių

Country Status (30)

Country Link
US (1) US10174035B2 (lt)
EP (1) EP3277682B1 (lt)
JP (1) JP6669417B2 (lt)
KR (1) KR20170131444A (lt)
CN (1) CN107428756B (lt)
AU (1) AU2016242080B2 (lt)
BR (1) BR112017020818A2 (lt)
CA (1) CA2980517C (lt)
CO (1) CO2017011020A2 (lt)
CY (1) CY1122018T1 (lt)
DK (1) DK3277682T3 (lt)
ES (1) ES2733505T3 (lt)
HK (1) HK1250161B (lt)
HR (1) HRP20190998T1 (lt)
HU (1) HUE045192T2 (lt)
IL (1) IL254688B (lt)
LT (1) LT3277682T (lt)
MX (1) MX2017012390A (lt)
MY (1) MY185268A (lt)
PH (1) PH12017501750A1 (lt)
PL (1) PL3277682T3 (lt)
PT (1) PT3277682T (lt)
RS (1) RS59213B1 (lt)
RU (1) RU2710549C2 (lt)
SG (1) SG11201706509QA (lt)
SI (1) SI3277682T1 (lt)
TR (1) TR201910941T4 (lt)
TW (1) TWI689508B (lt)
WO (1) WO2016157074A1 (lt)
ZA (1) ZA201705530B (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822336B2 (en) * 2016-09-29 2020-11-03 Daiichi Sankyo Company, Limited Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
CN110963955A (zh) * 2018-09-30 2020-04-07 南京富润凯德生物医药有限公司 一种单氟代螺环化合物的合成方法及其中间体
CN111087336A (zh) * 2018-10-24 2020-05-01 南京富润凯德生物医药有限公司 一种双氟代螺环化合物的合成方法及其中间体
CN110577515B (zh) * 2019-09-02 2022-05-17 南通大学 一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035740A2 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
KR101422301B1 (ko) * 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 약학적 화합물
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
CN101889015B (zh) 2007-10-05 2014-06-04 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
CA2703138A1 (en) 2007-10-26 2009-04-30 F. Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
WO2009146406A1 (en) 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
BRPI1009022A2 (pt) * 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
WO2010136491A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8288381B2 (en) 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
WO2012007493A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for ρi3κ p110 delta, and methods of use
JP5954838B2 (ja) 2010-09-14 2016-07-20 エクセリクシス, インク. Pi3k−デルタの阻害剤ならびにそれらの使用法および製造法
SI2651951T1 (sl) 2010-12-16 2015-01-30 F. Hoffmann-La Roche Ag Tricikliäśne p13k inhibitorske spojine in postopki uporabe
TW201309700A (zh) 2011-01-31 2013-03-01 Novartis Ag 新穎雜環衍生物
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物

Also Published As

Publication number Publication date
AU2016242080A1 (en) 2017-08-24
MX2017012390A (es) 2018-01-26
DK3277682T3 (da) 2019-07-29
SI3277682T1 (sl) 2019-06-28
HUE045192T2 (hu) 2019-12-30
HRP20190998T1 (hr) 2019-10-18
WO2016157074A1 (en) 2016-10-06
ZA201705530B (en) 2018-05-30
KR20170131444A (ko) 2017-11-29
CA2980517C (en) 2020-02-25
ES2733505T3 (es) 2019-11-29
CY1122018T1 (el) 2020-10-14
US20180072732A1 (en) 2018-03-15
BR112017020818A2 (pt) 2018-07-03
US10174035B2 (en) 2019-01-08
TWI689508B (zh) 2020-04-01
EP3277682B1 (en) 2019-04-24
RU2710549C2 (ru) 2019-12-27
CN107428756A (zh) 2017-12-01
CA2980517A1 (en) 2016-10-06
IL254688A0 (en) 2017-11-30
TW201643162A (zh) 2016-12-16
PH12017501750A1 (en) 2018-04-02
JP6669417B2 (ja) 2020-03-18
HK1250161B (zh) 2020-05-15
EP3277682A1 (en) 2018-02-07
CO2017011020A2 (es) 2018-01-16
RS59213B1 (sr) 2019-10-31
RU2017134110A3 (lt) 2019-06-11
MY185268A (en) 2021-04-30
PT3277682T (pt) 2019-07-09
SG11201706509QA (en) 2017-09-28
CN107428756B (zh) 2019-07-23
RU2017134110A (ru) 2019-04-03
IL254688B (en) 2021-03-25
TR201910941T4 (tr) 2019-08-21
AU2016242080B2 (en) 2019-09-19
JP2018510146A (ja) 2018-04-12
PL3277682T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
IL278916A (en) Benzoimidazole derivatives as PAD4 inhibitors
IL258081B (en) Benzimidazole history and their use
HK1248520A1 (zh) Egfr和pi3k的小分子抑制劑
IL254318A0 (en) History of benzaimidazoles as bromodomain inhibitors
AP2016009487A0 (en) Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
AP2015008783A0 (en) 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
HK1250926A1 (zh) 抑制劑及其應用
PL3362450T3 (pl) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
HUE047857T2 (hu) Bisz(szulfonamid) származékok és felhasználásuk mPGS-inhibitorként
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors